Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

María Díez-Campelo , José Lorenzo , Raphaël Itzykson , Silvia Rojas , Céline Berthon , Elisa Luño , Odile Beyne-Rauzy , Jaime Perez-Oteyza , Norbert Vey , Joan Bargay , Sophie Park , Teresa Cedena , Dominique Bordessoule , Juan C. Muñoz , Emmanuel Gyan , Esperanza Such , Sorin Visanica , Félix López-Cadenas , Stephane de Botton , Jesús Hernández-Rivas , Shanti Ame , Aspasia Stamatoullas , Jacques Delaunay , Celia Salanoubat , Pierre Isnard , Romain Guiéze (1) , Joan Pérez Guallar , Llorenc Badiella , Guillermo Sanz , Consuelo Cañizo , Pierre P. Fenaux

1 CHELTER - Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias

Domaines: Hématologie

María Díez-Campelo, José Lorenzo, Raphaël Itzykson, Silvia Rojas, Céline Berthon, et al.. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. British Journal of Haematology, 2018, 181 (3), pp.350 - 359. ⟨10.1111/bjh.15190⟩. ⟨hal-01780692⟩